본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Korean circulation journal v.35 no.12, 2005년, pp.877 - 882  
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

The Long-Term Clinical Outcomes of Combination Therapy with Angiotensin II Type 1 Receptor Blocker and Simvastatin after Percutaneous Coronary Intervention

Hong, Young Joon  
  • 초록

    BACKGROUND AND OBJECTIVES: Angiotensin II type 1 receptor blocker (ARB) has been to attenuate neointimal formation and vascular smooth muscle cell proliferation, with decreased inflammation. Recent studies have demonstrated that statins may contribute to the beneficial effects of ARB toward vascular diseases. The aim of this study was to evaluate the beneficial effects of the combination therapy of ARB and statin compared to that of angiotensin converting enzyme (ACE) inhibitor and statin in acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention (PCI). SUBJECTS AND METHODS: 396 patients with ACS, who underwent PCI between June 2002 and December 2003, were divided into two groups: the ARB and simvastatin (n=188, 61.2+/-10.3 years, male 72%) and ACE inhibitor and simvastatin groups (n=208, 60.9+/-10.6 years, male 66%). The major adverse cardiovascular events, including restenosis and repeat PCI, between the two groups were compared. RESULTS: At 6-month after PCI, the levels of total cholesterol, triglyceride and low-density lipoprotein cholesterol were significantly decreased and that of high-density lipoprotein cholesterol significantly increased, and the levels of high-sensitivity C-reactive protein, fibrinogen, white blood cell and monocyte significantly decreased in both groups. A quantitative coronary angiography analysis of stented coronary segments disclosed no differences in the minimum lumen diameter and stent length. At the 6-month follow-up angiogram, there were no significant differences in the incidence of restenosis and repeat PCI, and there was also no difference in late loss between the two groups (ARB and statin group: 20%, 18%, 0.78+/-0.38 mm vs. ACE inhibitor and statin group: 22%, 20%, 0.81+/-0.44 mm). There were no significant differences in the incidence of cardiac deaths, myocardial infarctions, cerebrovascular accidents and bypass grafts at the 1-year clinical follow-up between the two groups. The event-free survival rates at 1 year were 81 and 79% in the ARB and statin and the ACE inhibitor and statin groups, respectively. There were no differences in the late loss and major adverse cardiac events according to the used ARBs or ACE inhibitors. CONCLUSION: The combination therapy of ARB with statin might not show more beneficial effects compared to ACE inhibitor with statin in ACS patients having undergone PCI.


  • 주제어

    Angiotensin converting enzyme inhibitor .   Statins.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기